An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Sutro Biopharma to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) CEO Bill Newell to participate in three upcoming investor conferences to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference, TD Cowen 44th Annual Health Care Conference, and Barclays 26th Annual Global Healthcare Conference. Webcasts of the presentations will be accessible through the company’s website.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.
Conference Details:
Oppenheimer 34th Annual Healthcare Life Sciences Conference Date: February 13-14, 2024 Location: Virtual
TD Cowen 44th Annual Health Care Conference Date: March 3-6, 2024 Location: Boston
Barclays 26th Annual Global Healthcare Conference Date: March 12-14, 2024 Location: Miami
Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the event.
AboutSutroBiopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
When will CEO Bill Newell participate in the upcoming investor conferences?
CEO Bill Newell will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14, 2024, TD Cowen 44th Annual Health Care Conference on March 3-6, 2024, and Barclays 26th Annual Global Healthcare Conference on March 12-14, 2024.
Where will the investor conferences take place?
The Oppenheimer conference will be virtual, the TD Cowen conference will be in Boston, and the Barclays conference will be in Miami.
How can I access the webcasts of the presentations?
The webcasts will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com.
How long will the replays of the presentations be available?
Archived replays will be available for at least 30 days after the events.
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll